MEDP Medpacedata gap · 80% coverage
Health Care · Life Sciences Tools & Services · close $618.47 (2026-10-16) · latest quarter in EDGAR: 2026-06-30
Medpace (MEDP) has a ThetaGrade House Rating of 61/100 (grade C), ranking #78 of 150 in Health Care. Its strongest pillars are cash flow (76) and profitability (74); its weakest is valuation (45). Data gap: 4 factors without usable data, so 80% of the method weight is covered. TTM revenue growth is 24.7% and operating margin 21.0%.
Data as of .
Data gap
No usable data for: Consensus score (1–5), 90-day net rating shift, 4Q gross-margin change, Interest coverage. Data gap: no usable data for this factor, so it is left out and its weight is shared among the factors that do have data (no value is imputed). 80% of the full method weight is backed by data.
Analyst sentiment
weight 7.5% · no data · —| Consensus score (1–5) (0.0%)data gap | derived | — |
| 90-day net rating shift (0.0%)data gap | derived | — |
Growth
weight 30.83% (→33.3%) · 58| Revenue growth YoY (TTM) (13.3%) | 24.7% | 77 |
| EPS growth YoY (TTM) (13.3%) | 26.7% | 63 |
| Revenue acceleration (6.7%) | -9.3% | 9 |
Profitability
weight 18.5% (→20.0%) · 74| Operating margin (20.0%) | 21.0% | 74 |
| 4Q gross-margin change (0.0%)data gap | — | — |
Balance sheet
weight 18.5% (→20.0%) · 55| Net debt / EBITDA (13.3%) | -0.82× | 82 |
| Current ratio (6.7%) | 0.73 | 0 |
| Interest coverage (0.0%)data gap | — | — |
Cash flow
weight 12.33% (→13.3%) · 76| FCF margin (6.7%) | 26.9% | 89 |
| FCF yield (6.7%) | 3.9% | 62 |
Valuation
weight 12.33% (→13.3%) · 45| P/E (inverted) (6.7%) | 36.30× | 40 |
| EV/Sales (inverted) (6.7%) | 6.02× | 49 |
Technicals (EOD)
| RSI(14) | 53.5 |
| EMA 9 / 21 | 616.05 / 612.68 |
| 200-day SMA | 526.17 |
| Volume vs 20d avg | 1.22× |
| 20-day return | 0.5% |
Exit-rule monitor
No exit or watch rules triggered.
Data source per metric (SEC XBRL tag or derivation): Revenue: RevenueFromContractWithCustomerExcludingAssessedTax · Operating income: OperatingIncomeLoss · D&A: Depreciation · EPS: EarningsPerShareDiluted · Market cap: SEC shares (dei EntityCommonStockSharesOutstanding (cover page)) × EOD close · P/E: EOD close ÷ SEC TTM EPS (EarningsPerShareDiluted).
Get rating changes like MEDP's in the free Daily Brief
The market’s key events and signals, digested before the open.
- ✓ Pre-market Daily Brief: events, headlines, rating changes (2-min read)
- ✓ Sunday: Top 5 Weekly Picks, exit alerts, CSP put watchlist
- ✓ OPEX, FOMC, CPI and jobs-day reminders
Free. Want more? See Premium (waitlist).
FAQ
- What is MEDP's House Rating?
- MEDP scores 61 out of 100 (grade C) as of 2026-10-16, ranking #78 of 150 Health Care stocks we cover.
- What do analysts say about MEDP?
- We do not have enough analyst-sentiment data to score this stock.
- When does MEDP report earnings next?
- MEDP's next earnings report is estimated for about 2026-10-21 (window 2026-10-18 to 2026-10-31), based on its past SEC 8-K earnings filings. This is an estimate, not a company-confirmed date.
- Is MEDP a buy?
- ThetaGrade does not give personal advice. The House Rating is an educational, rules-based summary of public data; see the methodology for how it is built.
Sources: SEC EDGAR filings (fetched 2026-10-18), Finnhub recommendation trends, Massive EOD prices. Scores are sector percentiles; a factor without usable data is a data gap: it is left out and the remaining weights are renormalized (nothing is imputed). Educational only. Methodology